Skip to main content
. Author manuscript; available in PMC: 2025 Jan 1.
Published in final edited form as: J Heart Lung Transplant. 2023 Sep 17;43(1):148–157. doi: 10.1016/j.healun.2023.09.004

Table 5 –

Subgroup (Center-specific) Rejection Outcomes

DBD DCD p
n 1604 292
PRA >10% (%) 315 (21.6) 38 (15.3) 0.031
Peak PRA >10% (%) 402 (27.6) 52 (21.0) 0.035
Acute rejection prior to discharge (%) 336 (20.9) 68 (23.3) 0.412
Treated for acute rejection prior to discharge (%) 178 (11.1) 38 (13.0) 0.396
Treated for rejection within 1 year (%) 190 (11.8) 38 (13.0) 0.641
Hospitalized for rejection (%) 77 (13.8) 18 (23.4) 0.043
Follow-up time (months) for hospitalization for rejection (mean (SD)) 14.82 (5.64) 14.98 (6.04) 0.815
Hospitalized for infection (%) 221 (39.8) 33 (42.9) 0.700
Follow-up time (months) for hospitalization for infection (mean (SD)) 14.80 (5.63) 14.98 (6.04) 0.794
Coronary vasculopathy (%) 104 (9.6) 11 (6.3) 0.209
Follow-up time (months) for coronary vasculopathy (mean (SD)) 15.54 (5.74) 14.15 (5.38) 0.003